Home > Riviste > Minerva Surgery > Fascicoli precedenti > Minerva Surgery 2023 October;78(5) > Minerva Surgery 2023 October;78(5):481-9

ULTIMO FASCICOLO
 

JOURNAL TOOLS

Opzioni di pubblicazione
eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo
Share

 

ORIGINAL ARTICLE   

Minerva Surgery 2023 October;78(5):481-9

DOI: 10.23736/S2724-5691.23.09884-2

Copyright © 2023 EDIZIONI MINERVA MEDICA

lingua: Inglese

Surgery for locally advanced gastric cancer in the era of neoadjuvant therapies: something new?

Fausto ROSA 1, 2 , Vito LATERZA 1, Carlo A. SCHENA 1, Vincenzo TONDOLO 1, Antonia STRIPPOLI 3, Marcello COVINO 2, 4, Giovanni PACINI 1, Giuseppe QUERO 1, 2, Claudio FIORILLO 1, Davide DE SIO 1, Giampaolo TORTORA 3, Sergio ALFIERI 1, 2

1 Department of Digestive Surgery, IRCCS A. Gemelli University Polyclinic Foundation, Rome, Italy; 2 Sacred Heart Catholic University, Rome, Italy; 3 Department of Medical Oncology, IRCCS A. Gemelli University Polyclinic Foundation, Rome, Italy; 4 Department Emergency Medicine, IRCCS A. Gemelli University Polyclinic Foundation, Rome, Italy



BACKGROUND: Locally advanced gastric cancer (LAGC) represents a therapeutic challenge, particularly as it often involves adjacent organs. The necessity of neoadjuvant treatments for LAGC patients is still controversial. The aim of this study was to analyze the factors affecting prognosis and survival in patients with LAGC with particular regard to the effect of neoadjuvant therapies.
METHODS: Between January 2005 and December 2018, the medical records of 113 patients with LAGC who underwent curative resection were retrospectively reviewed. Patient characteristics, related complications, long-term survival, and prognostic factors were analyzed at uni- and multivariate analyses.
RESULTS: Postoperative mortality and morbidity rates of patients undergoing neo-adjuvant therapies were 2.3% and 43.2%, respectively. Whereas in patients undergoing upfront surgery were 4.6% and 26.1%, respectively. R0 resection was achieved 79.5% and in 73.9% of patients undergoing neoadjuvant therapy and upfront surgery, respectively (P<0.001). Multivariate analysis revealed that neoadjuvant therapy, completeness of resection (R0), number of lymph nodes retrieved, N status and the adoption of hyperthermic intraperitoneal chemotherapy were independent prognostic factors associated with longer survival. Five-year overall survival for NAC group and upfront surgery group was 46% and 32%, respectively (P=0.04). Five-year disease-free survival for NAC group and upfront surgery group was 38% and 25%, respectively (P=0.02).
CONCLUSIONS: Patients with LAGC undergoing surgery plus neoadjuvant therapy had a better OS and DFS with respect to patients treated with surgery alone.


KEY WORDS: Stomach neoplasms; Surgical operative procedures; Neoadjuvant therapy; Morbidity; Mortality

inizio pagina